Pentosan polysulfate sodium - Generic Drug Details

What are the generic drug sources for pentosan polysulfate sodium and what is the scope of freedom to operate?

Pentosan polysulfate sodium is the generic ingredient in one branded drug marketed by Janssen Pharms and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for pentosan polysulfate sodium. One supplier is listed for this compound.

Summary for pentosan polysulfate sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	1
Clinical Trials:	10
What excipients (inactive ingredients) are in pentosan polysulfate sodium?	pentosan polysulfate sodium excipients list
DailyMed Link:	pentosan polysulfate sodium at DailyMed

Recent Clinical Trials for pentosan polysulfate sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Paradigm Biopharmaceuticals Ltd.	PHASE3
TCM Biotech International Corporation	Phase 2/Phase 3
National Taiwan University Hospital	Phase 2/Phase 3

See all pentosan polysulfate sodium clinical trials

Pharmacology for pentosan polysulfate sodium

Drug Class

Glycosaminoglycan

Anatomical Therapeutic Chemical (ATC) Classes for pentosan polysulfate sodium

C05BA	Heparins or heparinoids for topical use
C05B	ANTIVARICOSE THERAPY
C05	VASOPROTECTIVES
C	Cardiovascular system

G04BX	Other urologicals
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for pentosan polysulfate sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ELMIRON	pentosan polysulfate sodium	CAPSULE;ORAL	020193-001	Sep 26, 1996		RX	Yes	Yes

Expired US Patents for pentosan polysulfate sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ELMIRON	pentosan polysulfate sodium	CAPSULE;ORAL	020193-001	Sep 26, 1996

EU/EMA Drug Approvals for pentosan polysulfate sodium

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
bene-Arzneimittel GmbH	Elmiron	pentosan polysulfate sodium	EMEA/H/C/004246Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.,	Authorised	no	no	no	2017-06-02

Pentosan polysulfate sodium Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Pentosan Polysulfate Sodium?

Pentosan polysulfate sodium (PPS) is a medication primarily approved for interstitial cystitis and is investigated for other indications such as osteoarthritis and anticoagulant uses. The drug’s market is influenced by regulatory approvals, clinical trial results, competitor landscape, and strategic partnerships.

Regulatory Environment

• Approval Status: PPS is approved in multiple countries for interstitial cystitis, notably in the U.S. (FDA approval) and EU. Its approval for other indications varies.
• Off-label Uses: Some physicians prescribe PPS for osteoarthritis and other conditions, although these are not officially approved uses.
• Recent Developments: The FDA approved a generic form of PPS in 2019, expanding availability but potentially impacting pricing and margins.

Market Drivers

• Increasing Prevalence: Interstitial cystitis affects approximately 3-8 million women and 1-4 million men in the U.S., driving consistent demand.
• Limited Competition: Few approved drugs for interstitial cystitis give PPS a dominant position.
• Clinical Trials: Ongoing studies for off-label indications, such as osteoarthritis and anticoagulation, could expand potential markets if successful.

Market Challenges

• Pricing and Reimbursement: Variability in insurance coverage and pricing pressures from generic manufacturers challenge revenue growth.
• Patent Expiry/Generics: Patent expiry and generic entry (notably after 2019 approval) reduce pricing power.
• Safety Profile: Bleeding risks linked with anticoagulant uses require careful patient selection and monitoring.

Competitive Landscape

• Existing Drugs: For interstitial cystitis, limited approved options include amitriptyline, pentosan remains preferred for some due to efficacy.
• Pipeline Products: No direct competitive drugs are in late-stage development; however, new treatments for interstitial cystitis are emerging.

Strategic Trends

• Market Expansion: Attempts to get approval for additional indications like osteoarthritis could open new revenue streams.
• Partnerships/Acquisition: Companies seek licensing or partnership deals to expand distribution channels and clinical research investments.

What Is the Financial Trajectory for Pentosan Polysulfate Sodium?

Financial outlook hinges on sales volumes, pricing strategies, market penetration, and operational costs.

Revenue Analysis

• Sales Data: Sales estimates vary, but recent industry reports suggest global PPS revenues of approximately $250 million in 2022, largely driven by North American markets.
• Growth Rate: Compound annual growth rate (CAGR) is projected at 3-4% over the next five years, constrained by market saturation for interstitial cystitis.

Cost Structures

• Manufacturing Costs: Production costs for PPS are relatively stable due to established synthesis processes, but biosimilar competition can pressure margins.
• R&D Expenses: Costs are increasing for clinical trials investigating additional indications—estimated at $10-15 million per phase III trial.

Market Penetration Strategies

• Expanding Indications: Successfully securing approval for new uses could increase sales; this requires investment in clinical studies and regulatory filings.
• Pricing Strategies: Price discounts could be implemented to enhance uptake amid generic competition, impacting profit margins.

Financial Risks and Opportunities

Risks	Opportunities
Patent expiration in 2019	Expanded indications for osteoarthritis and others
Pricing pressures from generics	Increased clinical trial success rates
Safety concerns limiting use	Strategic partnerships to expand distribution

What Are the Key Market Trends and Future Outlooks?

• Emerging Competitors: Development of novel interstitial cystitis treatments, including bladder instillations and neuromodulation devices, could threaten PPS market share.
• Market Saturation: Growth potential diminishes in mature markets like North America but remains viable in emerging markets.
• Regulatory Trends: Trends toward expedited approval pathways (e.g., FDA fast track) could shorten time to market for new indications.

Summary of Market and Financial Outlook

Pentosan polysulfate sodium holds a stable position within the niche of interstitial cystitis treatments. Market growth is modest, with potential expansion contingent on approval of additional indications and successful navigation of pricing pressures. Revenue projections suggest slow but steady growth, with opportunities tied to clinical development and strategic collaborations.

Key Takeaways

• PPS is approved for interstitial cystitis with a stable market primarily in North America and Europe.
• Patent expiry and generic competition constrain pricing and profit margins.
• Clinical trials for osteoarthritis and anticoagulant uses may expand market size.
• Revenues are approximately $250 million, with annual growth around 3-4%.
• Future growth depends on regulatory approvals, market expansion, and managing competitive pressures.

FAQs

1. What are the primary approved indications for PPS?
Interstimital cystitis in the U.S. and Europe.

2. When did PPS face patent expiration, and what was its impact?
Patent expiry occurred in 2019, leading to increased generic competition and pricing pressures.

3. Are there ongoing clinical trials for new PPS indications?
Yes, trials for osteoarthritis and anticoagulant-related uses are ongoing.

4. How does PPS compare pricing-wise with other treatments?
Generic PPS prices are lower than branded counterparts, but overall, PPS remains relatively expensive, especially for specialty uses.

5. What are the main risks for PPS revenues?
Generic competition, safety profiles limiting broader use, and emerging rivals in interstitial cystitis treatments.

---

References

1. DrugBank entry for Pentosan polysulfate sodium
2. FDA approval announcement for generic PPS
3. Market research report on interstitial cystitis therapies
4. ClinicalTrials.gov database for PPS studies